[PDF] Top 20 Perk Genetic Variation and Function in Progressive Supranuclear Palsy

... Though PERK null MEFs transiently expressing different variants of the PERK protein (HapA, HapB, 136C, 166Q, 704A) largely did not statistically differ from one another in pPERK, peIF2α, or ATF4 levels, ... See full document

... and progressive supranuclear palsy (PSP) represent neurodegenerative tauopathies with predominantly cortical versus subcortical disease ...a progressive weakening of the connectivity of these ... See full document

... RESULTS: Patients had lower functional connectivity than healthy subjects in all 5 resting-state networks, mainly involving the basal ganglia, thalamus, anterior cingulate, dorsolateral prefrontal and temporo-occipital ... See full document

... PET methods should also be considered. In particular, our main regional PET analyses used partial volume correction for CSF, which controlled for differences in CSF signal contam- ination within each region and across the ... See full document

... cognitive function than the MMSE and FAB, with a wider range of scores possible (maximum score 144), plus separate indices of memory (visual, verbal and total), attention (visual, verbal and total), response ... See full document

... addition, progressive resistance strength training is beneficial for gait, falls prevention and community ambulation ...with function and activity limita- tions can appear similar [16, ... See full document

... Our data suggest that global cognitive impairment and executive dysfunction are worst in PSP among the three groups. Patients with MSA had significant cognitive decline as opposed to previous experience. FAB scores and ... See full document

... Notes: Studies have demonstrated that disruption of microtubule structure and function has downstream consequences that ultimately lead to neurodegeneration and cell death. Among those effects initiated by ... See full document

... While NFTs are the main histological hallmark in PSP, tau, like other disease-associated amyloids, can form oligomers which then go on to form fibrils. Recent stud- ies from our laboratory and others have shown that tau ... See full document

... ing both reports it is clear that there is a marked trend toward reduced olfactory function in the pa- tients with PSP. Neither set of authors reported the results of subsequent power analysis, leaving open the ... See full document

... Measuring these different facets of awareness calls for several different approaches. ‘Metacognitive awareness’ is assessed by comparing self-ratings to significant other or clinician ratings, such as the Patient ... See full document

... With this aim in mind, we designed a phase I study, to test the safety of MSC administration in patients affected by PSP and to collect preliminary data on its efficacy. Herein we describe the evidence that we have ... See full document

... Head motion and image distortions induced by eddy currents in the DTI data were corrected by applying a 3D full-affine (mu- tual-information cost function) alignment of each image to the mean ... See full document

... visual function in the Parkinsonism syndromes have been divided into various categories based largely on those used to characterize vision in the dementias 58 and are summarized in Table ...visual function ... See full document

... PNFA: Progressive nonfluent aphasia; PSP: Progressive supranuclear palsy; PSP-RS: Progressive supranuclear palsy Richardson syndrome; Put: Putamen; R GP: Right globus ... See full document

... Progressive supranuclear palsy (PSP) is a disease entity defined neuropathologically by aggregates of the microtubule associated protein tau in astrocytes (tufted astrocytes), neurons ... See full document

... Regional cerebral cortical metabolic rates for glucose in the left hemisphere Aand in the right hemisphere B in patients with progressive supranuclear palsy PSPI expressedas a ratio to t[r] ... See full document

... gaze palsy), ‘round the houses’ sign, decreased blink rate, blepharospasm, and apraxia of eyelid opening, were selected based on their prevalence, distinctive fea- tures, and simplicity to elicit during a bedside ... See full document

... Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkin- son’s disease and t[r] ... See full document

... As regards to PSP, 313 participants were treated with 30 mg davunetide or placebo twice daily for 52 weeks in a randomized, double-blind, placebo-controlled trial. No significant effects were found on the ... See full document